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Background : Sildenafil, an oral phosphodiesterase type-5 inhibitor, has vasodilatory effects through a cyclic 
guanosine 3,5-monophosphate–dependent mechanism, whereas beraprost, an oral prostacyclin analog, induces 
vasorelaxation through a cAMP-dependent mechanism. This combination has often used but there was little 
detailed study on it
Objectives : To investigate whether the combination of oral sildenafil and beraprost is superior to sildenafil alone 
in in adult patients with Pulmonary Arterial Hypertention (PAH) related uncorrected secundum Atrial Septal 
Defect (ASD).
Methods : Patients with secundum ASD who developed PAH divided into two group. Group A received oral 
sildenafil 3x40 mg and oral beraphrost 3x20 mcg. Group B received oral sildenafil only 3x40 mg in a 12-week. 
Health-related quality of life (HRQoL) was recorded by patients using the Medical Outcomes Study 36-item short 
form (SF-36) questionnaires at baseline and after 12 of therapy. Therapy adherence was achieved through a 
series of phone calls and a four-weekly hospital visit. Every normal follow-up appointment included an examina-
tion of side effects and a dosage modification based on the clinical situation
Results: We didn’t found any significant of proportion different in cofounding factor between groups. Compared 
with Group B, Group A had better functional capacity, limitation to physical health, energy fatigue, pain, and 
health change (P=0.00, P=0.03, P=0.044, P=0.026, P=0.008, respectively).
Conclusion: Combination between oral sildenafil therapy 40 mg three times per day and beraphrost 20 mcg two 






 Pulmonary arterial hypertension (PAH) is a term used to 
classify a variety of conditions that have in common an injury to the 
pulmonary vasculature that produces elevations in pulmonary arterial 
pressure. PAH is a common (9–35%) consequence of congenital heart 
disease that primarily affects patients with a left-to-right shunt, includ-
ing an atrial septal defect (ASD) that has or has not been repaired. It is 
characterized by vascular remodeling, elevated pulmonary vascular 
resistance, and raised pulmonary arterial pressure.1 PAH had twice risk 
of mortality, three times risk of a cardiac event, and five times chance 
of ICU admission in ASD patients. Patients with PAH caused by 
uncorrected ASD are currently managed in tertiary care centers, where 
the development of advanced specific medications is expected to 
increase prognosis.2,3
 ASD patients who developed PAH could have symptom that 
reduced their quality of life such as dyspnea on effort, hemoptoe, 
dizziness, chest pain, palpitation, and peripheral edema. It’s impact on 
physical mobility and mental state that might deteriorate the patients’ 
health related quality of life (HRQoL).4 HRQoL is an indicator of 
personal satisfaction with one's life that is influenced by one's health 
condition, such as physical stamina, learning function, working 
relationships, emotional well-being, and spirituality. It is subjective, 
multifaceted, and transient. Quality of life in various chronic illnesses 
may be assessed using specialized and validated questionnaires such as 
the Short-Form 36 Health Survey (SF-36). This evaluation is highly 
repeatable, well-known, non-invasive, and extensively utilized survey is 
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 Sildenafil, an oral phosphodiesterase type-5 inhibitor, causes 
vasodilation via a cyclic guanosine 3’, 5’-monophosphate–dependent 
pathway, whereas beraprost, an oral prostacyclin analog, generates 
vasodilation via a cAMP-dependent function. When compared to 
treatment with either medication alone, combined treatment with 
sildenafil and beraprost exhibited additive effects on increases in 
plasma cAMP and cyclic guanosine 3’, 5’-monophosphate levels, 
resulting in additional improvement in pulmonary hemodynamics.6 
The combination of sildenafil and epoprostenol (intravenous prostacy-
clin analogue), however, has demonstrated synergistic effects. The 
PACES trial evaluated the benefit of sildenafil in patients on 
background epoprostenol therapy. This study included a total of 267 
patients and randomized patients to sildenafil or placebo. Sildenafil 
improved 6MWD by 28.8 meters (95% CI, 13.9 to 43.8 meters), and 
there were improvement in cardiac index and reductions mean PA 
pressures. Combined therapy yielded improvement in quality of life and 
time to clinical worsening although there were increased rates of 
headaches and dyspepsia.7
 HRQoL improvement has been reported in PAH related 
uncorrected ASD patients with the specific therapy, but it does not 
show consistency in combination of oral PDE5 inhibitor and oral 
prostacyclin analogue. Thus, we aim to investigate whether there are 
HRQoL differences between sildenafil mono therapy and combine with 
oral prostcycline analogue (Beraphrost)  in adult patients with PAH 
related uncorrected secundum ASD.
2. Method
 This was an observational prospective cohort study undertak-
en in the Saiful Anwar General Hospital, a Tertiary Hospital associated 
with Universitas Brawijaya in Malang, East Java, Indonesia. Adult 
patients (more than 18 years) with PAH and uncorrected secundum 
ASD who had enrolled on the Saiful Anwar-PH registry and signed the 
informed consent form were included in this study. Transthoracic 
echocardiography and transesophageal echocardiography were used to 
identify secundum ASD, whereas right cardiac catheterization was used 
to diagnose PAH. Exclusion criteria included failing to complete 
follow-up, having another congenital heart defect, being in WHO NYHA 
functional class I, being pregnant, or having chronic pulmonary illness-
es. In case report form, demographic and clinical data such as age, 
gender, WHO functional class, marital status, and concomitant illness 
were collected. Subjects completed an HRQoL questionnaire before and 
after receiving the optimum dose of oral sildenafil 3x40 mg (Group B) 
or in conjunction with an oral prostcycline analogue (Beraphrost 
3x20mcg) (Group A). Therapy adherence was achieved through a series 
of phone calls and a four-weekly hospital visit. Every normal follow-up 
appointment included an examination of side effects and a dosage 
modification based on the clinical situation.
2.1. Assessment of HRQoL 
 HRQoL in varied cardiac situations was assessed using the 
Short Form Survey (SF)-36 questionnaire. The HRQoL assessment was 
carried out to assess physical functioning, physical health limitations, 
emotional problems, energy/fatigue, emotional well-being, and social 
functioning.
2.2. Right heart catheterization (RHC)
 After TTE and/or TOE were verified as ASD and recorded, 
right heart catheterization (RHC) was simulated in all individuals. 
Before treatments, cardiology experts performed RHCs on non-sedated 
patients using conventional techniques. The RHC's goal was to compute 
hemodynamics, diagnose pulmonary artery hypertension (PAH), and 
assess the septal defect/shunt repair procedure. The flow rate was 
calculated using the formula pulmonary blood flow (Qp)/systemic 
blood flow (Qs) = (aorta saturation - mixed vein (MV) satura-
tion)/(pulmonary vein (PV) saturation-pulmonary artery (PA) satura-
tion). The MV saturation was calculated as ((3 x superior vena cava 
saturation) + inferior vena cava saturation)/4. The pulmonary vascular 
resistance index was used to develop the formula (mPAP-mean left 
atrial pressure (mLAP) (or mPAWP)/Qp) (PVRi). A Qp was calculated 
using the formula: O2 intake (ml/min)/ (1.36x10xhemoglobin level x 
((PV saturation-PA saturation-ation)/100).7 The PVR was calculated 
using the PVRi/body surface area. The PAH diagnosis was established 
when mPAP was 25 mmHg, PVR was greater than 3 WU, and PAWP or 
mLAP was greater than 15 mmHg.8 Eisenmenger syndrome is character-
ized when Qp/Qs = 1 and PVRi > 8 WU.m2. A vasoreactivity test was 
done on a subset of individuals (discretion by cardiologist consultants). 
The vasoreactivity result was determined using established recommen-
dations (reduction in PVR > 20% and final PVRi 6 WU.m2).9 Shunt 
correctability was defined as patients with appropriate defect anatomy 
(surgery and/or device), Qp:Qs > 2, and PVRi 6 WU.m2.8 Blood was 
drawn from each patient through venipuncture in peripheral veins and 
during RHC. Cuvettes analysis was used to measure the blood Gases 
analysis sample. The hemoglobin and hematocrit levels were 
determined using a standard hemocytometer.
2.3. Statistical Analysis
 The mean/median is used to represent continuous variables 
(interquartile range). Numbers and percentages are used to represent 
categorical variables. For comparisons between SF-36 domain 
subgroups, the Independent T-test was utilized (symptoms, activities 
and quality of life). Subgroups were established for continuous 
variables based on their median values. All statistical analyses were 
carried out utilizing the SPSS software, version 21 (SPSS Institute, Inc; 
Cary, North Carolina). If p < 0.05, the results were significant.
3. Result
 Forty-four patients were included to the analysis from the 
Saiful Anwar Pulmonary Hypertension Registry between January 2019 
until December 2020. As of 31 December 2020, at diagnosis, the mean 
age was 30.4 ± 8.2 years, The main symptoms were dyspnea on effort 
(35.9%), easily fatigued (16.3%), chest pain/discomfort (10.8%) and 
palpitations (9.3%). 20 patients got Sildenafil 3x40 mg, and 24 patients 
got combination between beraphrost 3x20 mcg and sildenafil 3x40 mg. 
We didn’t found any significant of proportion different in Comorbid 
condition between groups.
 Hemodynamic variables obtained during RHC (Table 2), that 
found no significant different level of hemodynamic variable between 
group. We found that, there were significant increasing for quality of 
live in group A compared with group B, there were significant different 
in physical functioning, Limitation to physical health, Energy fatigue, 
Pain, and health change (P=0.00, P=0.03, P=0.044, P=0.026, 
P=0.008, respectively).
4. Discussion
 The mean age of patient with ASD who developed PAH was 
similar to other studies, stated that PAH development in secundum ASD 
mostly occurred in the third decade. Incidence of PAH in secundum 
ASD were increased in patients at the age of 18 to 40 years old.10 
Dyspnea on effort was the most common symptom in this study, and its 
similar with previous studies stated that the most common symptom in 
uncorrected ASD who developed PAH was breathlessness due to 
volume overload of the right ventricle (RV).11
21




























Limitation due to physical health






























































































Note, data were presented in mean ±SD or n (%); NYHA = New York Heart Association (NYHA) Functional Classification; DOE = Dyspnea on Exertion; 
   PND =  Paroxysmal Nocturnal Dyspnea; HRQOL (SF-36)= Short-Form Health Survey.

































Note, data were presented in mean ±SD or n (%); ,MPAP = Mean pulmonary Arterial Pressure; MRAP = Mean Right Atrial Pressure; 
   LVEDP =  Left Ventricular End-Diastolic Pressure; PVR= Pulmonary Vascular Resistance.
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 The assessment of medication effects on HRQoL is a key 
component in assessing the impact of medicines on clinical outcomes 
and health care. Several prior studies that assessed HRQoL following 
sildenafil and beraphrost administration yielded results that were 
compatible with this study. Study by Joanna et al. (2008) found that 
after 12 weeks treatment, sildenafil-treated participants exceeded 
placebo-treated patients in terms of exercise ability (p 0.001). Increases 
in all SF-36 categories were seen in sildenafil-treated patients from 
baseline to week 12, with statistically significant increases in physical 
functioning (p 0.001), overall health (p 0.001), and vitality (p 0.05) 
compared to placebo-treated control individuals.12 Nazzareno Galiè et 
al. (2002) stated that Patients who received beraprost increased their 
exercise ability and symptoms, resulting in a higher quality of life.13,14 
 In this study, we found that combination of treatment 
between sildenafil and beraphrost had better quality of life compared 
than sildenafil alone. improve HRQoL measured by Medical Outcomes 
Study Short Form 36 (SF-36). Patients in group A had better physical 
functioning, lower limitation to physical activity, less energy fatigue 
and less pain.  SF-36 questionnaire is the most extensively used 
instrument for accessing HRQoL in various cardiac conditions. It can be 
used to accommodate eight health concepts. The improvement in the 
HRQoL can be achieved through several ways. Sildenafil relaxes the 
pulmonary vasculature via a cGMP-dependent pathway, whereas 
beraprost dilates the pulmonary arteries via a cAMP-dependent process. 
As a general pharmacologic concept, when various medicines that cause 
comparable effects via distinct pathways are combined, they may have 
additive or synergistic effects. In fact, as compared to therapy with 
either medication alone, the combination of oral sildenafil and 
beraprost substantially reduced increases in RV systolic pressure and 
RV/BW. These data imply that the combination of oral sildenafil and 
beraprost is more effective than either medication alone in preventing 
the development of MCT-induced pulmonary hypertension.13,6
 Although the drug administration significantly improves the 
SF-36 based on statistics, the clinical benefit cannot significant for 
patients. Thus, the score difference must exceed the MCID (Minimal 
Clinical Important Difference) that represent the minimal amount of 
benefit that were recognized by the patient. Using the distribu-
tion-based method, Koichi et al (2020) stated that the SF-36 MCIDs of 
the PCS (Physical component summery) and MCS (Mental component 
summery) were 5 and 5 by half the SD, and 6 and 5 by standard error 
of the measurement. we believe that the result can be used as a 
treatment consideration for pulmonary arterial hypertension cases 
especially in developing countries.
 We noticed several limitations in this study. First the sample 
size was small, further study with larger number of participants might 
23
be required. Second, we did not assess the effect of supportive 
treatments (such as diuretics, digoxin, oral anticoagulants), which is 
one of the PAH patient care methods specified in the ESC PAH recom-
mendations.8 Fluid retention, elevated central venous pressure, hepatic 
congestion, ascites, and peripheral edema are all symptoms of right 
heart failure. Although clinical experience suggests that diuretics might 
help minimize fluid retention symptoms, there have been no random-
ized studies including diuretic usage in PAH patients. Diuretic 
treatment is advised in PAH patients who show symptoms of right heart 
failure and fluid retention, according to the I C recommendation class. 
To avoid hypokalemia and pre-renal kidney disease, aldosterone 
antagonist treatment, combined with plasma electrolyte levels and 
renal function monitoring, may be explored.9
5. Conclusion
 This study concluded that combination between oral sildena-
fil therapy 40 mg three times per day and beraphrost 20 mcg two times 
per day in PAH patients in uncorrected secundum ASD significantly 
improve physical functioning, Limitation to physical health, Energy 
fatigue, Pain, and health change resulted in increasing HRQoL 
compared sildenafil alone. 
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  Table 3. Increasing Quality of Life According Group
Parameter
Physical Functioning
Limitation To Physical Health





































Note, data were presented in mean ±SD or n (%)
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